Background:: Haemorrhage is the leading cause of mortality during trauma. In 2012, London's Air Ambulance introduced Blood on Board (BOB), transfusing group O red cells (RBC) to trauma patients at the scene.
INTRODUCTION
Trauma is one of the world's leading causes of mortality, accounting for up to 5 million deaths per year (Haasgma et al., 2016) . Uncontrolled post-traumatic haemorrhage is the leading cause of death in these patients (Cothren et al., 2007) , and for this reason, a timely and organised approach to the management of bleeding is crucial to improving clinical outcomes.
Observational studies in military and civilian trauma bleeding patients have indicated that the transfusion of high ratios of plasma to red blood cells (RBC) units may improve morbidity and mortality, although the quality of the evidence for this so far is low (Murad et al., 2010) . The recent PROPPR trial showed a reduction in early exsanguination with a higher plasma to RBC ratio (Holcomb et al., 2015) . Current guidelines therefore recommend that fresh frozen plasma (FFP) should be given upfront during major haemorrhage of trauma and that the initial FFP : RBC ratio should be 1 : 1 (Hunt et al., 2015) . In order to allow for the early delivery of blood components during major haemorrhage, most hospitals have now established major haemorrhage protocols (MHP) as part of damage control resuscitation, and studies have demonstrated that MHP improve the administration of blood components and reduce wastage (Khan et al., 2013) . Other measures, such as the use of tranexamic acid, are also part of MHP to optimise haemorrhage control (Shakur et al., 2010) .
In the pre-hospital setting, when compared to crystalloid resuscitation alone, early transfusion with RBC and plasma improves early outcomes, although it did not have an effect on 30-day mortality (Holcomb et al., 2014) . However, the impact of pre-hospital transfusion on laboratory practice is unknown. Blood transfusion prior to group and screen (G&S) testing may result in a mixed field reaction, requiring further testing, and -in the case of urgent transfusion -the use of group O units until investigations can be completely resolved (Milkins et al., 2013) .
In March 2012, the London's Air Ambulance (LAA) started carrying group O-negative RBC for on-scene transfusion to trauma patients in an initiative known as Blood on Board (BOB). The aims of this study were to assess the impact of this on laboratory practice as examined by the number of mixed field samples received, the numbers of group O RBC transfused to non-group O patients and the RBC : FFP ratios.
METHODS
The London Trauma Network was established in 2008 to provide specialist and co-ordinated care to major trauma patients across the region and to collect data for the purposes of audit and research. Patients are seen by LAA and then transferred to one of the designated major trauma centres. During the study period, these trauma centres used the same MHP. Group O units were given before a blood group was established. One hospital within the London Trauma Network uses group O-positive RBC units for male patients and group O-negative RBC for female patients. The other trauma centres administer group O-negative RBC for all patients. Data were collected from August 2008 to February 2012 (pre-BOB) and from March 2012 until September 2013 (post-BOB) on all patients for whom the MHP was activated. Data were collected from LAA trauma office records and hospital transfusion laboratories. Information obtained included demographic data, the number of RBC units transfused by LAA and the destination of the patient (including death at the scene) and laboratory data, including G&S results. The number of group O and group-specific RBC transfused was recorded in addition to the number of other blood components issued in the first 24 h from the time of arrival at the hospital.
Group and Screen samples
All G&S samples were taken in ethylenediaminetetraacetic acid (EDTA) anticoagulated bottles and labelled with handwritten, unique trauma identifiers according to the hospitals' standard operating procedures. Samples were analysed as priority on arrival to the laboratory. Samples taken in the post-BOB group in patients who subsequently died at the scene were also taken to the laboratory. ABO and RhD typing was determined by a microplate haemagglutination technique in Centre A (Immucor-NEO, Immucor Inc., GA) and a gel card technique in Centres B and C (DiaMeD ID-System, BioRad Laboratories, BioMed GbmH, Switzerland). Mixed field samples were defined as those whose blood group could not be resolved by automation. For those patients who had a mixed field result detected by the automation method, manual testing using the DiaMeD system was performed.
Inadequately labelled samples were defined as those where the sample did not meet the identification criteria required by the laboratory policy.
Statistical analysis
Statistical analysis was performed using Stata 12 software (StataCorp. 2011. Stata Statistical Software: Release 12. College Station, TX: StataCorp LPv). The results are expressed as mean, median, In the pre-BOB group, 202 patients (87%) received a transfusion of any blood component. There was 100% traceability and no wastage. In the post-BOB group, 119 patients received a transfusion (100%) as part of BOB, and 83 patients (70%) received a subsequent transfusion of any blood components in hospital. Of the 36 patients not receiving any further transfusions after BOB, this included the 15 patients who died on the scene and the 21 patients who did not require further transfusion in hospital. The mean (standard deviation) RBC to FFP ratio was 1·6 (0·8) in the pre-BOB group and 1·7 (0·8) in the post-BOB group. There was no significant difference between the two groups (mean difference 0·13, 95% confidence interval 0·36-0·92). A total of 59% of the pre-BOB patients and 42% of the post-BOB patients had an RBC to FFP ratio of 2 : 1 or less.
Results of G&S samples are described in Table 2 . There was no significant difference in the percentage of mixed field samples pre-BOB vs post-BOB (P = 0·3).
An analysis of group O units transfused to non-group O patients was performed, and this is shown in Table 3 . There were 97 patients with a known non-group O blood group who received a transfusion of RBC in the pre-BOB group and 43 in the post-BOB group. Patients who did not receive any transfusion were excluded from analysis. The mean total number of RBC, mean total group O units and the proportion of total units given as group O are shown in Table 3 . There was no significant difference in the number of total RBC (P = 0·17), number of group O RBC (P = 0·29) or the percentage of total units given that were group O (P = 0·21). Patients were also categorised into those who received >95% of their total units as group O units or <95% group O RBC due to the wide range in the total number of units of RBC given and the difference in mean units given between the pre-BOB and post-BOB groups.
DISCUSSION
In this study, we have shown that following the introduction of BOB, there has been no significant difference in the proportion of mixed field samples received by the laboratory (23% vs 27%), suggesting that, post-BOB, G&S samples are being taken according to protocol, i.e. before transfusion. In addition, we have demonstrated that there is no increase in the percentage of group O-units transfused to non-group O patients and no change in RBC : FFP ratios. These findings are reassuring as they suggest that BOB is safe, does not lead to increased usage of group O units and is unlikely to significantly impact the laboratory workload. Although there is a decrease in what is deemed an acceptable sample, it is likely that this is largely due to fewer G&S samples being sent from severely injured patients who died either at the scene of the incident or just before arrival to the hospital in the pre-BOB era as there would not have been an indication to send samples until arrival at the trauma centre. Other possible reasons for a decrease in acceptable samples include failure to obtain a G&S sample prior to initiation of blood transfusion at the scene of the incident post-BOB, inappropriate labelling of blood samples leading to rejection by the laboratories or G&S samples being lost in the emergency department (due to chaotic nature of the situation) and not being sent to laboratories. We believe that the first reason is the most likely explanation as the teams managing these patients both pre-and post-BOB have remained largely the same, although we note the small increase in inadequate labelling, which may be due to increased workload at the scene; this is being addressed with LAA teams. We note that in mixed field results can vary depending on the technology used (UK NEQAS, 2016); however, the technologies used were consistent in each centre across the course of the study, and as the proportion of patient numbers from each centre was largely similar both pre-and post-BOB, we would not expect this to have a significant impact on the proportion of mixed field samples received.
We also note the increase in number of patients recorded to have died at the scene; however, due to the incomplete nature of the documentation, this was not always recorded, and it is possible that this is an underrepresentation of the true figure, particularly in the pre-BOB group, as in the post-BOB group, death at the scene was often recorded on the blood traceability form. This study was not powered to look for changes in mortality; however, this is clearly something that needs further investigation in subsequent research.
It can be anticipated that the increase in unacceptable or missing samples would lead to an increase in the workload for transfusion staff (as there will be more frequent need to contact clinical teams to request another G&S sample), and this could have an impact on other valuable transfusion services. Ideally, G&S samples should be taken at the time of intravenous cannulation by the LAA team prior to transfusion; however, it is acknowledged that in some cases, this will not be possible for clinical or practical reasons, and the priority must be early transfusion of blood components. Following the results of this study, we have introduced a G&S sample box that is sent to the laboratory together with the transfusion paperwork even in the event of the patient's death at the scene; if a G&S sample is not taken, the clinical team must indicate the reasons for not including it.
Two important and interesting findings are those regarding the ratio of group O units to non-group O patients and the RBC : FFP ratios. There was no significant increase in the proportion of group O units issued to non-group O patients. The most likely reason for this is the availability and accessibility of remote issue for group O RBC units in emergency departments and operating theatres, resulting in their high use both pre-and post-BOB. In the acute setting, it is very likely that clinicians are not aware when patients can be switched to group-specific RBC, and we are implementing systems to ensure that laboratory staff inform clinical teams when group-specific blood is available in order to reduce the inappropriate transfusion of group O RBC. The ratio of RBC : FFP did not change between the two groups following the introduction of BOB. This is reassuring and can be explained by the fact that the introduction of MHP in most trauma centres allows for FFP to be issued upfront as soon as the major haemorrhage protocol is activated, and we are considering the introduction of thawed plasma to the BOB packs. Although the rate was higher than the current recommendation of 1 : 1, it is consistent with the then recommended ratio of 6 : 4, which was part of the MHP used at the time, and we expect it to change in light of the new guidelines.
In conclusion, BOB appears to have led to an increase in the proportion of unacceptable G&S samples. This is likely to be due to an increase in cases in which no sample was received (probably due to the capture of patients dying at the scene in the post-BOB cohort). However, the proportion of group O RBC issued to non group O patients has not significantly increased; this is because almost half of non-group O patients in both the pre-and post-BOB groups are receiving >95% group O RBC in the initial 24-h period, even when patient's blood group is known. More work needs to be conducted to improve communication between pre-hospital and laboratory teams in order to optimise the quality of G&S samples received; this will enable patients to receive the most appropriate blood components as quickly as possible. The most efficient strategies for doing this need to be identified and the impact on laboratory and clinical outcomes measured. The BOB project is still in its early days; with increasing awareness and education, this can be improved.
